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ABSTRACT  
 
The surgical treatment of spinal metastases is evolving. The major problem is the 
selection of patients who may benefit from surgical treatment. One of the criteria is an 
expected survival of at least 3 months. A prediction model has been previously 
developed. The present study has been performed in order to validate externally the 
model and to demonstrate that this model can be generalized to other institutions and 
other countries than the Netherlands. Data of 356 patients from five centers in Germany, 
Spain, Sweden, and the Netherlands who were treated for metastatic epidural spinal 
cord compression were collected. Hazard ratios in the test population corresponded with 
those of the developmental population. However, the observed and the expected 
survival were different. Analysis revealed that the baseline hazard function was 
significantly different. This tempted us to combine the data and develop a new 
prediction model. Estimating iteratively, a baseline hazard was composed. An adapted 
prediction model is presented. External validation of a prediction model revealed a 
difference in expected survival, although the relative contribution of the specific hazard 
ratios was the same as in the developmental population. This study emphasized the need 
to check the baseline hazard function in external validation. A new model has been 
developed using an estimated baseline hazard. 
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1. INTRODUCTION 
 
The surgical treatment of spinal surgery is rapidly evolving. New insights contributed to 
this development. To be a surgical candidate, an expected survival of at least 3 months 
apart from other factors is mandatory [1]. 
 
Recently, a model to predict the survival of patients presenting with a spinal epidural 
metastasis has been developed [2]. The main purpose was to evaluate whether patients 
could be surgical candidates. Although the model was internally validated, external 
validation is recommended to demonstrate adequate, predictive performance in new 
patients in other hospitals, and also other countries [3, 4]. Therefore, this external, 
clinical validation including centers from several European countries was performed. 
 
 
1.1 PATIENTS AND METHODS 
 
Since the main interest of the study was testing the performance in groups of patients 
other than the study population, the model was geographically validated [5]. Several 
centers dealing with spine pathology in Europe were addressed. The centers were asked 
to provide data from a consecutive series of patients treated for spinal extradural 
metastasis within the same period as the original study population was recruited from. A 
computer-based form was offered. The following items were requested: date of birth, 
gender, site of primary cancer, date of diagnosis of primary, curative intention of 
treatment of primary, date of diagnosis of spinal metastasis, location of spinal 
metastasis-producing symptoms, metastasis confirmed by biopsy, Karnofsky 
Performance Score (KPS), instituted treatment, and date of death. 
 
 
1.2 STATISTICAL ANALYSIS 
 
Since in the development of the original model survival data were truncated at 10 
months to maintain the proportional hazard assumption, and the model is used to predict 
survival at 3 months, survival data are again truncated at 10 months. To evaluate 
predictive discrimination, the concordance (C) index was calculated [6]. The 
generalized R2Nagelkerke as a measure of predictive ability [6] that can range from 0 (poor) 
to 1 (perfect) was used. 
 
Missing data were managed in two ways. First, the cases with missing data were not 
included in the analysis, performing a complete case analysis. Second, multiple 
imputation was used for missing values. Logistic regression on the event indicator was 
used. Both sets of data were used for analysis, and presented. Heterogeneity between 
centers considering survival was tested using a log-rank test. 
 
Validation of the original model was done in several ways: fitting a Cox model on the 
test population, using the same predictors as did the original model, and then comparing 
the new estimates of the regression coefficients and associated hazard ratios (HRs) to 
those of the original model. Also, comparison of the new and original baseline hazard 
functions took place, using a method previously described [7, 8]. 
 
The observed survivals and the predicted survivals are graphically presented. The 
baseline survival function was checked for correctness [7]. The survival for patients 
predicted by the original model in the test population was compared to the observed 
survival. For this purpose, the test population was divided in quartiles considering the 
predicted linear part of the regression equation using the original model. In each 
quartile, the actual Kaplan–Meier estimate of the survival curve was compared with the 
averaged Cox-predicted survival curves. Ideally, these should be identical. 
 
To update the model, a new Cox proportional hazards model was constructed 
combining the test population and the original population using the same predictors. As 
already mentioned, missing data were imputed, and the Nelson–Aalen estimator of the 
cumulative hazard H0(T) was used as were other covariates for imputing a particular 
binary predictor that was fully missing in one of the test sites [9]. H0(T) was estimated 
iteratively in two cycles as has been described previously [9]. 
 
Imputation was performed five times, and by pooling the results, averaged estimates of 
the regression coefficients along with a variance–covariance matrix of the averaged 
estimates, adjusted for variability due to imputation, were obtained [10]. To assess the 
performance of this updated model, the median R2Nagelkerke and median concordance 
index c of the five models obtained after imputation were calculated. To be able to 
calculate and draw survival curves and associated 95% confidence bands, the survival 
curves resulting from the different imputations were averaged. 
 
1.3 SAMPLE SIZE 
 
Although recommended for the development for a new model [10], 20 patients at least 
per factor were included totaling at least 140 patients. 
 
 
2. RESULTS 
 
Five international centers responded to the invitation to participate. These were located 
in the Netherlands, Sweden, Germany (two centers), and Spain. The patients were 
treated between January 1996 and December 2008. Sixteen patients were diagnosed 
with spinal metastasis in 2008. 
 
A total number of 356 patients were included. Males outnumbered females: 217 versus 
139. Two hundred eighty-eight (80.9%) patients were dead. When the database was 
closed in April 2009, from eight patients was not known whether they were alive or not. 
The other patients were either dead or alive at least 3 months after the diagnosis of 
spinal metastasis. The median survival of the patients who died within the study period 
was 6.1±17.7 months. The location of the primary tumors was shown in Table 1. Thirty-
four patients underwent surgery prior to radiation therapy. Sixteen patients underwent a 
combined treatment of surgery, chemotherapy, and radiation therapy. The remaining 
306 patients received radiation therapy solely. In 124 (34.8%) patients, the diagnosis 
was confirmed histologically by a biopsy of the vertebral lesion. 
 
Of one center, it was not known whether the primary cancer was treated with curative 
intention. Therefore, in 60 patients, the data on curative intention of the treatment of the 
primary were missing. For these, multiple imputation was used. 
 
In Table 2, the estimated coefficient in the final proportional hazards model is 
represented based on the data of the test population including the data that have been 
multiple imputed. Since only two patients were included with a KPS of 10–20, the 
estimated hazard ratio was extremely high and did not contribute to the estimation of 
the expected survival time. Furthermore, the 95% CI was very wide. Therefore, these 
patients were excluded from further analysis in the test population. 
 
Comparing observed survival time with the predicted survival time resulted in 
differences (Fig. 1). Analysis of the correctness of the baseline survival function 
showed a significant difference between original population and the validation 
population (Fig. 2). 
 
The hazards of the two populations were disproportionate. This is a remarkable and 
unexpected finding. The hazard ratios using the data of the test population were 
comparable with the hazard ratios form the original model. Also, their relative 
contribution within the respective models was nearly equal. 
 
To meet the goal of a prediction model that could be used in many centers, a new model 
has been developed combining the data of the original and test population. All five 
imputed prediction models were pooled. 
 
The model was built on the data of 567 patients. The results are represented in Table 3. 
Examples of the prediction model are shown in Fig. 3 and Table 4. Because of the 
pooling, R2Nagelkerke and C index cannot be determined in a standard fashion. However, 
based on five imputations using the Nelson–Aalen estimator, median R2Nagelkerke is 0.318 
(minimum 0.314, maximum 0.320), and median C index is 0.719 (minimum 0.718, 
maximum 0.721). The model that can be consulted on the web (www.nccn.nl) has been 
adapted accordingly. 
 
 
3. DISCUSSION 
 
One of the most important factors that has to be considered by the physician in order to 
tailor a palliative treatment to the individual patient with spinal metastasis is the 
patient's survival prognosis. It has been shown that an estimation based on clinical 
grounds is inaccurate [11, 12]. Recently, this inaccuracy has been demonstrated in a 
phase II trial. One of the incision criteria was a life expectancy of at least 2 years 
determined by the investigator. More than half of the patients did not survive as long as 
12 months [13]. Decision support is one of the major purposes of a prediction model 
[6]. 
  
Therefore, models to estimate the survival of patients presenting with a spinal 
metastasis have been developed. The prediction for survival is, for example, important 
to choose between long—or short—course radiotherapy [14]. The predicted survival 
apart from other factors also determines whether a patient will be a surgical candidate 
[1]. 
 
A model to predict survival of patients in order to decide for surgery was published 
previously [2]. Although internally validated, transportability to other cohorts of 
patients was not proven. Therefore, an external validation is warranted. During this 
procedure, the model should be kept as simple as it was, and the urge to improve the 
model by adding predictive factors should be repressed [15]. 
 
Whether the survival of patients can be influenced by surgery is still matter of research. 
In the study by Patchell et al., in selected cases, only a small difference was found [16]. 
The major advantage of surgery was improvement of the quality of life. It can be argued 
whether survival can be improved by removing a metastatic lesion in the spine. Firstly, 
it cannot be removed with adequate margins. Secondly, a metastatic lesion of the spine 
is an expression of systemic disease that will not be influenced by removing one small 
part of it. Therefore, a correction for surgical intervention was not done. 
 
During the external validation, the hazard ratios were nearly in the same range as in the 
original model. Also, the internal relationship of the hazard ratios did not differ 
significantly. 
   
However, major differences occurred comparing the observed survival time and the 
expected survival time. The expected survival was in all cases too restrictive. Evaluation 
of the possible cause learned that the baseline hazard of the validation population was 
completely different. Many explanations are possible. The genetic constitution and 
therefore the influence of a malignancy could be different in the two populations. Race 
was not incorporated in the predictors. We do not believe this is of influence since all 
patients are living in Western Europe. Another possibility was that treatments were 
different. We doubt this is the right explanation since most of the patients were only 
treated by radiation therapy. As was proven by Patchell [16], surgery did not contribute 
to a major difference in survival. The selection of not all relevant predictors in the 
original set of data is also a possibility. However, selection was done according to 
commonly accepted procedures. Bootstrapping confirmed the internal validity of the 
model [2]. 
 
After interpretation of the results, two options were considered. Firstly, the model 
should not be changed, since we demonstrated that the predictors in the original model 
were adequate, but the baseline hazard function was dissimilar. However, this would 
interfere with generalizability, and our underlying goal. The model was not meant to be 
used only in Nijmegen. 
 
Secondly, the model could be adapted combining the data of the two populations. In our 
opinion, this was appropriate since the relative contribution of the predictors was nearly 
the same in both populations. Only the baseline hazard was different. Therefore, the 
combined data were used to develop a new model. The major advantage was that it was 
constructed from a larger and different population. The relative contribution of the 
hazard ratios was again nearly the same as in the original model. However, the 95% CI 
are more narrow as can be expected since the number of patients was larger. Especially, 
considering R2Nagelkerke and C index, we are convinced that the current model more 
accurately predicts the survival in different geographical settings. 
 
Our study has some limitations. Although the study population is retrieved from 1996 
till 2008, development of new medicines, alternative radiation schemes, or more 
aggressive surgical intervention may have contributed to an improved survival. 
However, the study by Patchell did not show a major contribution of surgery to survival 
[16]. Multiple imputation was used for missing values. This enabled us to use data on 
other predictors. It has been shown that the used method of multiple imputation did 
provide a lower bias to the null than older ones as, for example, the multiple imputation 
based on log T [9]. Growing evidence is available supporting the use of multiple 
imputation instead of complete case analysis [17]. However, more complete data would 
have been preferable. 
 
Currently, prospectively data are collected to validate further the prediction model 
externally. These will be separately presented. This study proofed that external 
validation was obligatory before using a prediction model clinically. In our opinion, this 
was the first time that a difference in baseline hazards had been shown during an 
external validation process. Future investigations should pay explicitly attention to the 
baseline hazards of the original and test population. 
 
In conclusion, an externally validated and adapted model is presented to predict the 
survival of patients presenting with spinal metastasis. The model is especially appealing 
since knowledge of only five clinical parameters is necessary. Furthermore, this model 
can be used in multiple countries. Incorporation of this model in daily practice will 
certainly contribute to an improvement of the quality of the care for the patients with 
spinal metastatic disease 
 
Disclaimer: None 
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Table 1. Location of primary tumor 
Gender   
Female Male 
Total 
Location Prostate 0 61 61
 Breast 64 3 67
 Lung 23 66 89
 Kidney 7 17 24
 Other 44 71 115
Total  138 218 356
 
 
 
 
Table 2. Comparison of hazard ratios estimating an unfavorable outcome when using the data from 
the original population, the test population without imputation, and also the test population after 
multiple imputation for the missing data of curatively intended treatment of the primary tumor. 
 Estimated HR in original model 
Estimated HR in test 
population without 
imputation 
Estimated HR in test 
population after 
multiple imputation
Number of patients 219 286 346 
Variable  
Gender (female versus male) 0.669 0.572 0.616
Lung carcinomaa 2.232 2.788 2.391
Kidney carcinomaa 2.798 2.116 2.449
Other carcinomaa 2.052 1.595 1.680
Curatively intended treatment 
of primary tumorb 0.675 0.790 0.709 
Cervical location of spinal 
metastasisc 1.630 1.528 1.676 
KPS (10–20) 31.455 – –
KPS (30–40) 7.687 5.599 7.275
KPS (50–70) 5.670 4.475 4.627
KPS (80) 4.446 2.143 2.041
HR hazard ratios, 95% CL 95% confidence limits, KPS Karnofsky Performance Score. 
For the test population, it is assumed that the baseline hazard is the same as in the original population
a The HR was calculated compared with patients with breast or prostate carcinoma. 
b This is a true or false expression. It is true when considering histology, location, and extension of 
the primary tumor (including metastases), the initial treatment is aimed at cure. When the treatment is 
palliative, the expression is false. 
c Although in other parts of the spine metastases can be present, the symptomatic metastases should 
be present in the cervical spine. 
 
 
 
 
 
Table 3. Hazard ratios estimating an unfavorable outcome when using the combined data         
from the original and test population 
Variable 
Estimated coefficient in 
original proportional 
hazards model 
HR 95% CL        for the HR P 
Gender (female versus male) −0.473 0.623 0.491–0.79 <0.0001
Lung carcinomaa 0.639 1.894 1.401–2.562 <0.0001
Kidney carcinomaa 0.924 2.520 1.642–3.868 <0.0001
Other carcinomaa 0.546 1.725 1.319–2.257 <0.0001
Curatively intended treatment 
of primary tumorb −0.368 0.692 0.540–0.887 0.004 
Cervical location of spinal 
metastasisc 0.841 2.318 1.684–3.189 <0.0001
KPS (10–20) 4.393 80.918 33.275–196.774 <0.0001
KPS (30–40) 2.314 10.117 5.318–19.246 <0.0001
KPS (50–70) 1.654 5.228 2.826–9.671 <0.0001
KPS (80) 1.344 3.836 1.954–7.529 <0.0001
HR hazard ratios, 95% CL 95% confidence limits, KPS Karnofsky Performance Score. 
The total number of patients is 567. 
a The HR was calculated compared with patients with breast or prostate carcinoma. 
b This is a true or false expression. It is true when considering histology, location, and extension of 
the primary tumor (including metastases), the initial treatment is aimed at cure. When the treatment 
is palliative, the expression is false. 
c Although in other parts of the spine metastases can be present, the symptomatic metastases should 
be present in the cervical spine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4. Prediction of survival at 3 months and after 6 months after the first diagnosis of spinal 
metastasis using the model developed combining the original data                                 
and the data of the patients collected for external validation 
Gender 
Primary 
tumor treated 
curatively 
Primary 
tumor KPS, range
Cervical 
location 
Survival at         
3 month 
Survival at        
6 month 
F + Breast 50–70% − 0.87 (0.83–0.91) 0.75 (0.69–0.81) 
F − Breast 50–70% − 0.81 (0.76–0.87) 0.66 (0.59–0.74) 
F + Breast 50–70% + 0.72 (0.63–0.82) 0.51 (0.39–0.66) 
F − Breast 50–70% + 0.62 (0.52–0.74) 0.38 (0.27–0.54) 
F + Breast 80% − 0.90 (0.86–0.94) 0.81 (0.74–0.88) 
F − Breast 80% − 0.86 (0.81–0.91) 0.74 (0.65–0.83) 
F + Breast 80% + 0.79 (0.70–0.88) 0.61 (0.49–0.77) 
F − Breast 80% + 0.71 (0.60–0.83) 0.49 (0.36–0.67) 
M + Prostate 50–70% − 0.80 (0.74–0.85) 0.63 (0.55–0.72) 
M − Prostate 50–70% − 0.72 (0.66–0.79) 0.51 (0.43–0.61) 
M + Prostate 50–70% + 0.59 (0.47–0.74) 0.34 (0.22–0.53) 
M − Prostate 50–70% + 0.47 (0.35–0.63) 0.21 (0.12–0.39) 
M + Prostate 80% − 0.85 (0.79–0.91) 0.71 (0.62–0.81) 
M − Prostate 80% − 0.79 (0.72–0.86) 0.61 (0.51–0.73) 
M + Prostate 80% + 0.68 (0.56–0.82) 0.46 (0.31–0.67) 
M − Prostate 80% + 0.57 (0.44–0.74) 0.32 (0.19–0.54) 
M + Kidney 80% − 0.66 (0.53–0.81) 0.43 (0.28–0.65) 
M − Kidney 80% − 0.54 (0.40–0.74) 0.29 (0.16–0.54) 
M + Kidney 80% + 0.38 (0.21–0.66) 0.14 (0.04–0.43) 
M − Kidney 80% + 0.24 (0.11–0.54) 0.06 (0.01–0.29) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1. A difference is shown between the observed (dashed line) and the expected 
survival without shrinkage (dotted line) and with shrinkage (solid line). The data were 
divided in quartiles based on the Predictive Index. Those with the best prognosis are 
represented in a and subsequently in b, c, and d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Direct comparison of log cumulative baseline hazard function disclosing a 
significant difference in slope (P<0.0001). 
***Original population. 
●●●Test population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 3. Predicted survivals of patients with the same characteristics as previous 
published [2]. a Prostate carcinoma, KPS 80%, no cervical location, and curative 
intention of primary. b As a except KPS 50–70% and cervical metastasis. c Renal cell 
carcinoma, KPS 80%, noncervical, curative intention treatment of primary. d Same as c 
except cervical location and noncurative intention treatment primary. 
